8-K: Nektar Therapeutics Sells Manufacturing Business to Ampersand Capital Partners for $90 Million

Nektar Therapeutics has agreed to sell its Alabama manufacturing facility and reagent supply business to Ampersand Capital Partners for $90 million, including cash and equity.

Summary

• Nektar Therapeutics has entered into an agreement to sell its manufacturing facility in Huntsville, Alabama, to Ampersand Capital Partners.
• The total purchase price is $90 million, consisting of $70 million in cash and $20 million in equity in a new Ampersand portfolio company.
• Ampersand will also invest additional growth equity capital into the new company.
• The sale is expected to close by December 2, 2024, subject to customary closing conditions.
• Nektar will retain all rights to current and future royalty streams and milestones related to existing PEGylated product license agreements.
• Nektar will enter into manufacturing supply agreements with the new company to meet its PEG reagent needs.
• All Nektar employees at the Huntsville facility will be offered employment at the new portfolio company.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strategic divestiture, extended cash runway, and continued supply agreements. However, there are some risks associated with relying on a third party for manufacturing.

Positives

• The sale allows Nektar to streamline its operations and focus on core R&D programs in immunology.
• The transaction extends Nektar's cash runway into the fourth quarter of 2026.
• The agreement ensures continued supply of PEGylation reagents for Nektar's needs.
• Ampersand's investment will support the growth of the Huntsville facility as a standalone business.
• Nektar will retain a board seat in the new Ampersand portfolio company.

Negatives

• Nektar is divesting a commercial-scale manufacturing facility, which could impact future revenue streams.
• The company will now rely on a third party for its PEG reagent supply.

Risks

• The transaction is subject to customary closing conditions, which could delay or prevent the sale.
• There is a risk that the new company may not be able to maintain the same level of quality and reliability in manufacturing.
• Nektar will be dependent on the new company for its PEG reagent supply, which could create supply chain risks.
• The transition of employees to the new company could lead to disruptions in operations.

Future Outlook

The sale is expected to extend Nektar's cash runway into the fourth quarter of 2026, and the company will focus on its core R&D programs in immunology. Nektar will also enter into manufacturing supply agreements with the new company to meet its PEG reagent needs.

Management Comments

• Howard W. Robin, President and CEO of Nektar Therapeutics, stated that the sale streamlines Nektar's operations and allows the company to focus on the clinical advancement of its immunology pipeline assets.
• David Anderson, General Partner at Ampersand Capital Partners, expressed being impressed with the manufacturing capabilities at the Huntsville facility and looks forward to investing in and growing the site as a stand-alone business.

Industry Context

This announcement reflects a trend of biotechnology companies streamlining operations and focusing on core research and development activities. The sale of manufacturing assets to private equity firms is also a common strategy for companies looking to raise capital and reduce operational costs.

Comparison to Industry Standards

• The sale of a manufacturing facility for $90 million is a significant transaction in the biotech industry, especially for a company like Nektar that is shifting its focus to R&D.
• The structure of the deal, including cash and equity, is a common approach in private equity acquisitions.
• The involvement of Ampersand Capital Partners, a firm with a strong track record in life sciences, suggests a strategic move to enhance the value of the manufacturing business.
• Comparable transactions in the biotech sector often involve similar considerations, such as retaining supply agreements and ensuring continuity of operations.

Stakeholder Impact

• Shareholders will benefit from the extended cash runway and focus on core R&D.
• Employees at the Huntsville facility will be offered employment at the new portfolio company, ensuring job continuity.
• Customers of Nektar's PEGylation reagents will continue to be served by the new company.
• Nektar will have a reliable supply of PEGylation reagents for its own needs.

Next Steps

• The transaction is expected to close by December 2, 2024, subject to customary closing conditions.
• Nektar and the new Ampersand portfolio company will enter into manufacturing supply agreements.
• Nektar will appoint a representative to the board of the new Ampersand portfolio company.

Key Dates

Keywords

Nektar Therapeutics, Ampersand Capital Partners, manufacturing facility, PEGylation, reagent supply, biotechnology, private equity, asset sale, Huntsville, immunology